Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients

Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients

Despite increasing clinical interest in adapting checkpoint inhibitor (CPI) therapies for patients with gynecologic malignancies, no accurate clinical biomarkers to predict therapy response and prognosis are currently available. Therefore, we aimed to assess the predictive and prognostic value of pr...

Full description

Bibliographic Details
Main Authors:	Thomas Bartl, Arina Onoprienko, Gerda Hofstetter, Leonhard Müllauer, Nina Poetsch, Thorsten Fuereder, Paul Kofler, Stephan Polterauer, Christoph Grimm
Format:	Article
Language:	English
Published:	MDPI AG 2021-11-01
Series:	Biomolecules
Subjects:	immunotherapy immune checkpoint inhibitor biomarker overweight RECIST
Online Access:	https://www.mdpi.com/2218-273X/11/11/1700

Similar Items

Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
by: Hyo Jung Park, et al.
Published: (2021-01-01)

Erratum: Tumor response assessment on imaging following immunotherapy
by: Frontiers Production Office
Published: (2023-03-01)

Tumor response assessment on imaging following immunotherapy
by: Antonia M. Berz, et al.
Published: (2022-10-01)

The Prognostic Value of the Fibrinogen-Albumin-Ratio Index (FARI) in Patients with Advanced Vulvar Cancer
by: Arina Onoprienko, et al.
Published: (2022-11-01)

Evaluation of liver tumour response by imagingKey points
by: Jules Gregory, et al.
Published: (2020-06-01)

BUSCANDO UNA CURVA GENERAL DE RESPUESTA A LA QUIMIOTERAPIA BASADA EN LA EVALUACIÓN RADIOLÓGICA CON CRITERIO RECIST
by: Mauricio Canals L, et al.

Tumor Response Evaluation Using iRECIST: Feasibility and Reliability of Manual Versus Software-Assisted Assessments
by: Inka Ristow, et al.
Published: (2024-02-01)

Are radiologists ready to evaluate true response to immunotherapy?
by: Inci Kizildag Yirgin, et al.
Published: (2021-02-01)

A pretreatment transcriptomic signature that predicts outcomes of immunotherapy in melanoma
by: Junjie Hu, et al.
Published: (2022-12-01)

Computed Tomography and Spirometry Can Predict Unresectability in Malignant Pleural Mesothelioma
by: Alice Bellini, et al.
Published: (2021-09-01)

Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience
by: Caroline Touloupas, et al.
Published: (2021-10-01)

Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group – ESOI Joint Paper
by: Laure Fournier, et al.
Published: (2022-01-01)

Diffusion-weighted MR imaging diagnostic merits in the post-therapeutic assessment of musculoskeletal soft tissue sarcoma
by: Amr Farouk Ibrahim Moustafa, et al.
Published: (2019-11-01)

Tumor Response Criteria in Oncoimaging: RECIST Criteria and beyond—Part 2
by: Akshay D. Baheti, et al.
Published: (2019-08-01)

A single‐institution pediatric and young adult interventional oncology collaborative: Novel therapeutic options for relapsed/refractory solid tumors
by: Raja Shaikh, et al.
Published: (2023-06-01)

Imaging biomarkers for evaluating tumor response: RECIST and beyond
by: Ching-Chung Ko, et al.
Published: (2021-07-01)

Immunotherapy Assessment: A New Paradigm for Radiologists
by: Vincenza Granata, et al.
Published: (2023-01-01)

iRECIST: how to do it
by: Thorsten Persigehl, et al.
Published: (2020-01-01)

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives
by: Vivek Subbiah, et al.
Published: (2017-02-01)

Response Assessment of Treated Hepatocellular Carcinoma
by: Amitkumar J. Choudhari, et al.
Published: (2023-09-01)

Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial
by: Masahiro Hatooka, et al.
Published: (2018-06-01)

Development of an algorithm for evaluating the impact of measurement variability on response categorization in oncology trials
by: Jeong-Hwa Yoon, et al.
Published: (2019-05-01)

Elevated tumor markers for monitoring tumor response to immunotherapy
by: Yi Yang, et al.
Published: (2022-04-01)

Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib
by: Joon-Il Choi, et al.
Published: (2014-06-01)

RECIST 1.1 and lesion selection: How to deal with ambiguity at baseline?
by: Antoine Iannessi, et al.
Published: (2021-03-01)

Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
by: Meihua Wang, et al.
Published: (2019-02-01)

Clinical Practice Guidelines for Immune Checkpoint Inhibitor Therapy in Gynecological Tumors
by: Gynecological Oncology Society of Chinese Medical Association
Published: (2021-11-01)

Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1
by: Angelo Castello, et al.
Published: (2020-07-01)

Imaging of tumour response to immunotherapy
by: Clarisse Dromain, et al.
Published: (2020-01-01)

Predicting the radiotherapeutic treatment response of non-small cell lung cancer
by: Soumyajit Das, et al.
Published: (2022-01-01)

Imaging response assessment for oncology: An algorithmic approach
by: Kathleen Ruchalski, et al.
Published: (2022-01-01)

Response criteria in solid tumors (PERCIST/RECIST) and SUVmax in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy
by: Cory Pierson, et al.
Published: (2018-02-01)

Pretreatment visceral metastases in castration resistant metastatic prostate cancer: role in prediction versus actual site of disease progression
by: Kathleen Ruchalski, et al.
Published: (2022-07-01)

Modeling tumor measurement data to predict overall survival (OS) in cancer clinical trials
by: Fang-Shu Ou, et al.
Published: (2021-09-01)

The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy
by: Wenxiao Jia, et al.
Published: (2019-12-01)

Role of multislice computed tomography 3D volumetric analysis in the assessment of the therapeutic response of hepatocellular carcinoma after transarterial chemoembolization
by: Mohamed Fouad Osman, et al.
Published: (2021-07-01)

Prognostic role of pre-chemotherapy platelet counts in patients with non-small cell lung cancer treated with first-line chemotherapy at IRD SMS medical college Jaipur
by: Kalim Khan, et al.
Published: (2020-01-01)

Body size perceptions and preferences favor overweight in adult Saharawi refugees
by: Desire Alice Naigaga, et al.
Published: (2018-02-01)

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
by: Alessio Cortellini, et al.
Published: (2019-02-01)

Long-term survival in multiresistant metastatic choriocarcinoma after pembrolizumab treatment: A case report
by: V. Paspalj, et al.
Published: (2021-08-01)